COVID-19 bites into Pfizer’s Q3, but biopharma revenues risePfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company Share XCOVID-19 bites into Pfizer’s Q3, but biopharma revenues risehttps://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/
GSK starts 2020 on a high, but warns of tougher times aheadGlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving Share XGSK starts 2020 on a high, but warns of tougher times aheadhttps://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/
Pfizer will start COVID-19 vaccine trial in US next weekPfizer is preparing to start clinical trials of its COVID-19 candidate in the US next week, and says Share XPfizer will start COVID-19 vaccine trial in US next weekhttps://pharmaphorum.com/news/pfizer-will-start-coronavirus-vaccine-trial-in-us-next-week/
Lilly raises 2020 earnings forecast on pandemic stockpilingStockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s first-quarter results, and Share XLilly raises 2020 earnings forecast on pandemic stockpilinghttps://pharmaphorum.com/news/lilly-raises-2020-earnings-forecast-on-pandemic-stockpiling/
Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challengeEli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but Share XLilly’s diabetes med Trulicity shrugs off Novo Nordisk challengehttps://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/
Novartis results show Zolgensma early growth wasn’t a flukeNovartis’ bumper crop of new product launches in 2019 helped it post 9% sales growth in the fourth Share XNovartis results show Zolgensma early growth wasn’t a flukehttps://pharmaphorum.com/news/novartis-results-show-zolgensmas-early-growth-wasnt-a-fluke/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
